ICH Q8 (R2) Pharmaceutical development - Scientific guideline
HumanScientific guidelines
This document describes the suggested contents for the 3.2.P.2 (Pharmaceutical Development) section of a regulatory submission in the ICH M4 Common Technical Document (CTD) format. The guideline also indicates areas where the demonstration of greater understanding of pharmaceutical and manufacturing sciences can create a basis for flexible regulatory approaches.
Keywords: Pharmaceutical development, quality, quality by design, enhanced approach, design space, proven acceptable ranges, process analytical technology, risk assessment, control strategy
Current effective version
Related content
- ICH: quality
- Quality: manufacturing
- Quality: pharmaceutical development
- Quality: Quality by Design (QbD)
European Medicines Agency-Food and Drug Administration pilot programme for parallel assessment of quality-by-design applications: lessons learnt and questions and answers resulting from the first parallel assessment- ICH-endorsed guide for ICH Q8/Q9/Q10 implementation
- Questions and answers on design-space verification
- Questions and answers on level of detail in the regulatory submissions
- Training material for Q8/Q9/Q10
- ICH Q9 Quality risk management
- ICH Q10 Pharmaceutical quality system
- Need for a reflection paper on quality aspects of medicines for older people
- Pharmaceutical development of medicines for paediatric use
- Questions and answers on implementing the ICH guidelines Q8, Q9 and Q10
- Real time release testing
- Use of near infrared spectroscopy (NIRS) by the pharmaceutical industry and the data requirements for new submissions and variations